What “mimetic” means
“Mimetic” simply means imitator. An incretin mimetic is a drug built to imitate your body’s own incretin hormones — the gut signals, chiefly GLP-1, that fire after a meal and nudge the pancreas toward releasing insulin. Your natural incretins do this job well but break down within minutes. The engineering breakthrough behind modern medications was to copy the hormone’s shape closely enough to switch on the same receptors, while resisting that rapid breakdown — so a single weekly dose keeps working for days.
Why the whole GLP-1 class fits the label
Every drug in the GLP-1 family is an incretin mimetic. Semaglutide (Ozempic, Wegovy) copies GLP-1. Tirzepatide (Mounjaro, Zepbound) goes further, copying both GLP-1 and GIP at once as a dual agonist. Because they act on the same receptors as your natural incretin hormones, they produce the same downstream effects — lower blood sugar after eating, slower stomach emptying, and reduced appetite — just amplified and sustained.
What to keep in mind
“Incretin mimetic” is a mechanism label, not a specific product. It tells you how a drug works, not which brand you’re taking or at what dose. The category is also expanding: newer molecules add targets beyond the incretins, such as the glucagon or amylin systems. If you’re weighing options, the useful takeaway is that these medications don’t override your biology — they lean on a signaling system your body already uses. For specifics on any one drug, the GLP-1 class overview and your prescriber are the places to go.